Brief: Data On Potential Biomarker For Qualigen Therapeutics’ Lead Program QN-302 Published In Peer-Reviewed Journal Molecules
08/03/2023 15:55
March 8 (Reuters) - Qualigen Therapeutics Inc QLGN.O :
* DATA ON POTENTIAL BIOMARKER FOR QUALIGEN THERAPEUTICS’
LEAD
PROGRAM QN-302 PUBLISHED IN PEER-REVIEWED JOURNAL MOLECULES
Source text for Eikon: ID:nGNXcbKBD8
Further company coverage: QLGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aixcrypto Holdings
See all newsBrief: Aixcrypto - Enters Common Shares Purchase Agreement With Gold King Arthur Holding - SEC Filing
Chief Executive Officer And Director
Brief: Aixcrypto Holdings - Enters Note Purchase Agreement With CABG Acquisition Corp On May 12, 2026 - SEC Filing
Brief: Aixcrypto Holdings Reports First Quarter 2026 Results
AIxCrypto Q1 net loss widens as expenses rise